发明名称 |
CANCER COMBINATION THERAPY WITH A SELECTIVE INHIBITOR OF HISTONE DEACETYLASE HDAC1, HDAC2 AND/OR HDAC3 AND A MICROTUBULE STABILIZER |
摘要 |
The invention relates to the treatment of mammalian disease manifested by abnormal cell growth and/or abnormal cell proliferation. More particularly, the invention relates to the use of combination therapies to control abnormal cell growth and/or abnormal cell proliferation. In particular, the invention relates to the use of isotype-selective inhibitors of histone deacetylases 1, 2 and/or 3 (HDACs 1-3), as well as isotype-selective inhibitors of HDAC1 and/or HDAC2, to potentiate therapeutic activity of microtubule-stabilization agents.
|
申请公布号 |
KR20100072024(A) |
申请公布日期 |
2010.06.29 |
申请号 |
KR20107008151 |
申请日期 |
2008.09.12 |
申请人 |
METHYLGENE INC.;TAIHO PHARMACEUTICAL CO., LTD. |
发明人 |
LI ZUOMEI;MURAKAMI KOJI |
分类号 |
A61K31/506;A61K31/337;A61K31/402;A61P35/00 |
主分类号 |
A61K31/506 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|